Naloxone has been used as a treatment to reduce the effects of an opioid overdose for a long time. However, the USFDA has recently revised the recommended dosage of naloxone nasal spray. Read the article to know more. The USFDA has approved the use of 8 mg naloxone nasal spray to treat opioid overuse. Previously, 2 mg and 4 mg doses were approved.
Upon quick and timely administration, naloxone is known to significantly reduce the effects of opioid overdose, within minutes. Further recommendations from the USFDA are: Manufacturers should pursue the approval of over-the-counter naloxone products. Manufacturers of all opioid pain relievers and medicines to treat opioid use disorder should add new recommendations about naloxone to the prescribing information. The shelf life of naloxone nasal spray to be increased from 24 months to 36 months. The key objectives of FDA in combating opioid…
